Multaq

Multaq contains the active ingredient dronedarone, an antiarrhythmic drug manufactured by Sanofi-Aventis. First approved by the FDA in 2009, dronedarone was developed as a structurally modified version of amiodarone, one of the most effective but also most toxic antiarrhythmic agents available. Multaq was designed to retain the antiarrhythmic benefits of amiodarone while reducing the risk of organ toxicity, particularly to the thyroid, lungs, and liver.

How Multaq Works

Dronedarone has a complex mechanism of action that affects multiple ion channels in the heart. It blocks sodium, potassium, and calcium channels, and it also has anti-adrenergic properties. By acting on these pathways, Multaq helps stabilize the electrical activity of the heart and maintain a normal sinus rhythm after cardioversion (a procedure that restores normal heart rhythm). Unlike amiodarone, dronedarone does not contain iodine in its chemical structure which is why it carries a significantly lower risk of thyroid complications. Patients managing cardiovascular conditions may also want to explore other medications in our heart health medications catalog.

Clinical Effectiveness

The clinical benefit of Multaq was primarily established in the ATHENA trial, a large placebo-controlled study involving over 4,600 patients with atrial fibrillation or atrial flutter. This study demonstrated that dronedarone significantly reduced the combined endpoint of cardiovascular hospitalization or death from any cause. The reduction in hospitalization was largely driven by fewer admissions related to atrial fibrillation recurrence. However, a separate study (PALLAS) in patients with permanent atrial fibrillation found that dronedarone actually increased the risk of cardiovascular events in that population, which is why Multaq is strictly contraindicated in permanent AF. For patients also managing their blood pressure, it’s important that all cardiac medications are coordinated by a physician.

Dosing Guidelines

The recommended dose of Multaq is 400 mg taken twice daily — once with the morning meal and once with the evening meal. Taking dronedarone with food significantly increases its absorption, so it should always be administered with a meal. If a dose is missed, patients should take the next dose at the regularly scheduled time and should not double up. Grapefruit juice must be avoided as it can increase dronedarone blood levels through CYP3A4 inhibition.

Patients should not stop taking Multaq without consulting their doctor first, as sudden discontinuation could lead to recurrence of atrial fibrillation. Before starting treatment, your physician should confirm that you are in normal sinus rhythm, and appropriate antithrombotic therapy (such as blood thinners) should be in place. Patients who are also taking Xarelto or Eliquis for stroke prevention related to AFib should ensure their anticoagulation therapy is properly managed alongside Multaq.

Who Should Not Take Multaq

Multaq is contraindicated in several important patient groups. It must not be used in patients with permanent atrial fibrillation (who cannot or will not be restored to normal sinus rhythm), as clinical trials showed increased cardiovascular risks in this population including a higher rate of stroke and heart failure hospitalizations. It is also contraindicated in patients with NYHA Class IV heart failure or Class II–III heart failure with a recent decompensation requiring hospitalization.

Other contraindications include severe liver impairment, a QTc Bazett interval of 500 ms or greater, a PR interval greater than 280 ms, second- or third-degree heart block, and a resting heart rate below 50 bpm without a pacemaker. Multaq should not be used alongside strong CYP3A4 inhibitors (such as ketoconazole, ritonavir, or clarithromycin) or other Class I or III antiarrhythmic drugs. Pregnant women must not take Multaq, as animal studies showed the drug can cause fetal harm. Patients who have experienced liver toxicity related to previous amiodarone use should also avoid dronedarone.

Comparing Multaq to Other Antiarrhythmics

Multaq occupies a unique position among antiarrhythmic drugs. Compared to amiodarone, it is less effective at maintaining sinus rhythm but carries a much more favorable side effect profile — particularly the absence of thyroid, pulmonary, and ocular toxicities. Other antiarrhythmics used for atrial fibrillation include flecainide and propafenone (Class IC agents) and sotalol and dofetilide (other Class III agents). The choice between these medications depends on the patient’s underlying heart condition, kidney function, and other risk factors. Patients who also take heart rate-controlling medications like Coralan (ivabradine) should be aware that dronedarone can interact with drugs that slow heart rate. Our blog on blood pressure treatment comparisons may also provide useful background for patients managing multiple cardiac medications.

Storage and Handling

Store Multaq tablets at room temperature between 68°F and 77°F (20°C to 25°C), with brief excursions allowed between 59°F and 86°F. Keep the tablets in their original packaging and away from moisture. As with all prescription medications, store out of the reach of others.

Buying Multaq Online

If you’re looking to buy Multaq online or order prescription medication at a more affordable price, licensed international pharmacies can offer meaningful savings. At our online pharmacy, Multaq is available as both the brand-name Sanofi product and the Droncor generic, each containing 400 mg of dronedarone in 60-tablet packs. Orders over $150 ship free, and all products are sourced from licensed dispensaries.